Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P22004

UPID:
BMP6_HUMAN

ALTERNATIVE NAMES:
VG-1-related protein

ALTERNATIVE UPACC:
P22004; Q5TCP3

BACKGROUND:
The Bone morphogenetic protein 6, known for its alternative name VG-1-related protein, plays a crucial role in various developmental processes, including bone and cartilage formation. It significantly influences iron metabolism by regulating HAMP/hepcidin expression through its action as a ligand for hemojuvelin. BMP6 initiates the BMP signaling cascade, interacting with type I and II receptors, and can signal through alternative pathways, such as the TAZ-Hippo, to affect VEGF signaling.

THERAPEUTIC SIGNIFICANCE:
Given BMP6's critical role in managing iron homeostasis and its association with iron overload, exploring its functions and signaling mechanisms offers a promising avenue for developing targeted therapies. Understanding the role of Bone morphogenetic protein 6 could open doors to potential therapeutic strategies, especially for conditions related to iron metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.